Highest-materiality recent filing
MindWave, a wholly owned Apimeds (NYSE American: APUS) subsidiary, will deploy its MindChain infrastructure to power AQUAEChain under a 12-month agreement with AQUAE Holdings.
Apimeds completes 1-for-10 reverse stock split; share count falls to 1.51M
Reverse stock split effective 12:01 a.m. ET on July 24, 2026; every 10 shares combined into 1 share.
Apimeds acquires Apitox rights from FreeT: Korean clinic market, 25% US royalty
On Aug 19, 2026, Apimeds entered an Assignment Agreement with FreeT Inc. (successor to CNP Roen/Inscobee).
Apimeds Pharmaceuticals announces 1-for-10 reverse stock split effective July 24, 2026
Reverse stock split at 1-for-10 ratio, effective 12:01 a.m. ET on July 24, 2026.
Apimeds settles merger dispute; Lokahi provides $4M working capital; board to transition
Settlement resolves all disputes from Dec 2025 Merger Agreement; Lokahi retains Apitox program assets valued at ~$2.2M.
Apimeds gets NYSE American delisting notice for late 10-K; trading halt continues
Received NYSE American notice on April 17, 2026 for failure to file 2025 10-K on time.
Apimeds expects NYSE notice for late 10-K filing; targets April 30
Filed Form 12b-25 on March 31, 2026 for FY 2025 10-K; will not file within 15-day extension.
Apimeds: Majority stockholder consent to remove directors/officers is null and void
Inscobee Inc. and Apimeds, Inc. attempted written consent to remove directors Kogan, Koo, O’Donnell, Weintraub and officers Menon (CEO) and Frim (CFO).
On March 20, 2026, Inscobee and Apimeds Korea claimed to remove all four directors and CEO/CFO via written consent.
Apimeds US board and CEO ousted; new board approves expansion into Korean cosmetics and photo booth
Majority stockholders removed directors Elona Kogan, Jakap Koo, Carol O’Donnell, Dr. Bennett Weintraub via written consent.
MindWave posts six-month net loss $6.6M on zero revenue; digital assets $132.3M
Net loss $6.6M for six months ended Sep 30, 2025 vs net income $57.8M in prior year period.
Apimeds corrects Merger Agreement errors: Preferred Stock issuance rises to 90.9% of equity
Corrected Merger Agreement removes Sections 2.05(b)/(d) (director appointment).
On Dec 1, 2025, Apimeds (APUS) merged with MindWave Innovations, with MindWave surviving as wholly owned subsidiary.
Apimeds Pharmaceuticals US completes $13.5M IPO; starts trading on NYSE American
IPO of 3,375,000 shares at $4.00/share; gross proceeds $13.5M.
the Board appointed Sungjoon Chae to serve as a member of the Board, effective as of such date.
On May 4, 2026, pursuant to a nomination by a stockholder of Apimeds Pharmaceuticals US, Inc., a Delaware corporation (the " Company "), the board of directors of the Company (the " Board ") appointed Sungjoon Chae to serve as Co-Chief Executive Officer of the Company, effective as of such date.
Under the Settlement Agreement, the Inscobee Parties have agreed to secure the resignation or removal of Mr. Koo.
On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
On May 30, 2025, the Board of Directors of Apimeds Pharmaceuticals US, Inc. (the “Company”) appointed Erick J. Frim as Chief Financial Officer of the Company, replacing Mark Corrao.
Max materiality 1.00 · Median 0.57 · Most common event other_material